Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A

As of June 30, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 5.41B, placing it among publicly traded companies globally. Its enterprise value stands at 5.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A has 420.78M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.63, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A recorded 10.91M in income tax expense.

As of the close on October 22, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 7.24% over the past 52 weeks. The 50-day moving average sits at 15.78, while the 200-day moving average is 16.05.

As of June 30, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A holds 487.46M in cash and equivalents against 748.31M in total debt, resulting in a net debt position of 297.03M. Total book value stands at 914.83M, with working capital of 385.42M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu Aidea Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.04 per share.